Replies to post #336420 on Avid Bioservices Inc (CDMO)

[EndoTarget]

You'll remember with the SUNRISE failure a table of miRNA biomarkers that could be the next step of anti-PS bla bla bla.

OncXerna like in Moderna (COVID...)

The mRNA and miRNA is the future of "precision" or personalized therapy.

Expect a lot of money and research for the next 10-15 years.

Avid has a bright future.

BTW Oncxerna is formerly known as Oncologie and anything they successfully commercialized or sublicenced gives AVID royalties when based on transferred technologies related to the selling of assets in 2018...

[EndoTarget]

On the basis of these positive data, the company also announced its rebranding to OncXerna Therapeutics, Inc., a change that reinforces the company’s focus on using its RNA-based approach to guide novel, targeted treatments to specific people with cancer.

“With a deep understanding of the tumor microenvironment biology at the RNA-level through our novel biomarker panel, we aim to dramatically improve clinical outcomes by matching patients to therapies with a mechanism of action that targets that specific biology,” said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics